Recombinant human platelet-activating factor acetylhydrolase for treatment of severe sepsis: Results of a phase III, multicenter, randomized, double-blind, placebo-controlled, clinical trial*Steven M. Opal, John P. Pribble, Xavier Wittebole et al.|Critical Care Medicine|2004Cited by 145
Recombinant platelet-activating factor acetylhydrolase to prevent acute respiratory distress syndrome and mortality in severe sepsis: Phase IIb, multicenter, randomized, placebo-controlled, clinical trial*Daniel P. Schuster, John P. Pribble, Steven M. Opal et al.|Critical Care Medicine|2003Cited by 82
CD14 receptor occupancy in severe sepsis: Results of a phase I clinical trial with a recombinant chimeric CD14 monoclonal antibody (IC14)*Konrad Reinhart, John P. Pribble, Jan Bakker et al.|Critical Care Medicine|2004Cited by 80
Longitudinal studies of inter-alpha inhibitor proteins in severely septic patients: A potential clinical marker and mediator of severe sepsis*Steven M. Opal, Sonia Souza, Edward Siryaporn et al.|Critical Care Medicine|2007Cited by 62